HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- PARP inhibitors take big step toward changing practice
-
- Will the use of PARP inhibitors in advanced ovarian cancer with wild-type BRCA lead to improved OS rates?
- Oncology Care Model: Progress along the learning curve John Sweetenham, MD, FRCP, FACP
- NCI-sponsored clinical trials cost-effective, ‘practice influential’
- Programs aim to address ‘pending and widening gap’ in palliative care workforce
- Olaparib trial reveals ‘first personalized treatment strategy for prostate cancer’
- Cabazitaxel improves outcomes among certain men with metastatic prostate cancer
- Circulating tumor DNA ‘a major prognostic factor’ in colorectal cancer
- Nivolumab-ipilimumab combination benefits women with advanced cervical cancer
-
- Rivoceranib fails to significantly improve OS in advanced gastric cancer
- Surgical exploration ‘highly recommended’ after induction chemotherapy for locally advanced pancreatic cancer
- Ribociclib-fulvestrant combination extends OS among postmenopausal women with advanced breast cancer
- Immunotherapy combination improves OS compared with chemotherapy in lung cancer subset
- Tumor mutational burden does not predict efficacy of pembrolizumab, chemotherapy for advanced NSCLC
- Single-agent, targeted therapies induce negligible response among smokers with NSCLC
- Autoantibody blood test improves lung cancer detection
- MicroRNA blood test enhances results of low-dose CT screening for lung cancer
-
- ESMO presents awards to four clinicians
- Pregnancy, preeclampsia linked to higher risk for transfusion reactions
- Malnutrition common among older patients with cancer
- Ibrutinib plus rituximab 'more effective and less toxic' than chemoimmunotherapy for chronic lymphocytic leukemia
- Enfortumab vedotin induces responses in advanced urothelial cancer
- FDA warns breast cancer treatments may lead to rare but severe lung inflammation
- FDA approves Nubeqa for prostate cancer subset
- Ohio State’s cancer hospital names CEO
-
- Radiation oncologist inducted into honorary police surgeons society